MAR 31, 2019 7:30 PM PDT

Chemopreventative Drug Targets H. Pylori Infections

WRITTEN BY: Nouran Amin

A chemopreventative drug being tested for its ability to inhibit the production of cell growth in multiple types of cancer was found to act directly on the bacterium Helicobacter pylori (H. pylori)--specifically during the treatment process of preventing stomach cancer.

According to a study published in the Proceedings of the National Academy of Sciences, the chemopreventative drug--DFMO (difluoromethylornithine)—was found to reduce the virulent characteristics of an H. pylori infection which serves as the primary cause of gastric cancer, the third leading cause of cancer deaths worldwide.

The H. pylori bacterium infects roughly half of the human population, but only 1 percent of the infected individuals will develop stomach cancer. Although the infection is treatable for stomach cancer prevention, it is not exactly clear who can or can’t be treated. Additionally, the infection might actually incur beneficial effects as esophageal reflux diseases, asthma and other allergic disorders will occur more frequently in those infected with H. pylori.

Learn more about H. pylori infections:

"H. pylori has co-evolved with humans for at least 60,000 years, probably longer, and attempting to prevent stomach cancer by eliminating the infection with widespread use of antibiotics is not necessarily a good idea," said Keith Wilson, MD, Thomas F. Frist Sr. Professor of Medicine and professor of Pathology, Microbiology and Immunology. "Our study suggests that it might be possible to reduce the virulence of the bacteria, without having to eliminate it. It's a speculative and unusual way to think about an infection, but it could be an interesting strategy."

DFMO was demonstrated in H. pylori-infected animal models to inhibit an enzyme responsible for the production of polyamines, which are cell growth compounds implicated in the development of stomach cancer. These research findings are now the basis of an ongoing clinical trial where DFMO is being used for stomach cancer prevention in Honduras and Puerto Rico.

Source: Vanderbilt Medical University

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
OCT 15, 2020
Cannabis Sciences
Can Cannabis Treat Traumatic Brain Injury?
OCT 15, 2020
Can Cannabis Treat Traumatic Brain Injury?
Traumatic brain injury (TBI) happens when the head is violently hit by an object or when an object pierces the skull and ...
OCT 03, 2020
Drug Discovery & Development
Treating Gut-Leakiness
OCT 03, 2020
Treating Gut-Leakiness
A drug called tofacitinib, also called Xeljanz , was found to treat permeability defects in the intestines. Tofacitinib ...
OCT 20, 2020
Drug Discovery & Development
The Power of Extracellular Vesicles
OCT 20, 2020
The Power of Extracellular Vesicles
What are extracellular vesicles (EVs)? They are tiny nanometer sized messengers that transport themselves between cells ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 20, 2020
Drug Discovery & Development
Hyperbaric Oxygen Treatments Reverse Aging
NOV 20, 2020
Hyperbaric Oxygen Treatments Reverse Aging
Researchers from Israel have found that hyperbaric oxygen treatments (HBOT) in healthy aging adults can prevent blood ce ...
Loading Comments...